Skip to main content
TipRanks
Go Ultimate75% OFF

Genor Biopharma Holdings Limited (67N0) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Genor Biopharma Holdings Limited has a market cap or net worth of EUR 362.28M. The enterprise value is EUR 3.62B.

Market Cap
EUR 362.28M
Enterprise Value
EUR 3.62B

Share Statistics

Genor Biopharma Holdings Limited has 2,014,126,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
2,014,126,200
Owned by Insiders
―
Owned by Institutions
―

Financial Efficiency

Genor Biopharma Holdings Limited’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 10.13%.

Return on Equity (ROE)
0.11
Return on Assets (ROA)
0.07
Return on Invested Capital (ROIC)
10.13%
Return on Capital Employed (ROCE)
0.16
Revenue Per Employee
1.80M
Profits Per Employee
288.87K
Employee Count
1,499
Asset Turnover
0.41
Inventory Turnover
2.17

Valuation Ratios

The current PE Ratio of Genor Biopharma Holdings Limited is 4.30. Genor Biopharma Holdings Limited’s PEG ratio is 0.01.

PE Ratio
4.30
PS Ratio
0.74
PB Ratio
0.66
Price to FCF
4.81
Price to Operating Cash Flow
4.39
PEG Ratio
0.01

Income Statement

In the last 12 months, Genor Biopharma Holdings Limited had revenue of 2.70B and earned 433.01M in profits. Earnings per share was 0.23.

Revenue
2.70B
Gross Profit
1.76B
Operating Income
689.46M
Pretax Income
538.21M
Net Income
433.01M
EBITDA
933.65M
Earnings Per Share (EPS)
0.23

Cash Flow

In the last 12 months, operating cash flow was 600.32M and capital expenditures -53.81M, giving a free cash flow of 546.51M billion.

Operating Cash Flow
600.32M
Free Cash Flow
546.51M
Free Cash Flow per Share
0.27

Dividends & Yields

Genor Biopharma Holdings Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
20.86%
Earnings Yield
16.38%

Stock Price Statistics

Beta
0.34
52-Week Price Change
-51.42%
50-Day Moving Average
0.18
200-Day Moving Average
0.23
Relative Strength Index (RSI)
35.63
Average Volume (3m)
8,060

Important Dates

Genor Biopharma Holdings Limited upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).

Last Earnings Date
Aug 28, 2026
Next Earnings Date
Mar 31, 2027
Ex-Dividend Date
―

Financial Position

Genor Biopharma Holdings Limited as a current ratio of 1.00, with Debt / Equity ratio of 38.57%

Current Ratio
1.00
Quick Ratio
0.80
Debt to Market Cap
0.32
Net Debt to EBITDA
0.46
Interest Coverage Ratio
3.86

Taxes

In the past 12 months, Genor Biopharma Holdings Limited has paid 105.20M in taxes.

Income Tax
105.20M
Effective Tax Rate
0.20

Enterprise Valuation

Genor Biopharma Holdings Limited EV to EBITDA ratio is 2.66, with an EV/FCF ratio of 5.29.

EV to Sales
0.81
EV to EBITDA
2.66
EV to Free Cash Flow
5.29
EV to Operating Cash Flow
4.81

Balance Sheet

Genor Biopharma Holdings Limited has EUR 913.17M in cash and marketable securities with EUR 1.18B in debt, giving a net cash position of -EUR 269.05M billion.

Cash & Marketable Securities
EUR 913.17M
Total Debt
EUR 1.18B
Net Cash
-EUR 269.05M
Net Cash Per Share
-EUR 0.13
Tangible Book Value Per Share
EUR 0.25

Margins

Gross margin is 62.60%, with operating margin of 26.67%, and net profit margin of 12.09%.

Gross Margin
62.60%
Operating Margin
26.67%
Pretax Margin
15.64%
Net Profit Margin
12.09%
EBITDA Margin
30.47%
EBIT Margin
26.67%

Analyst Forecast

The average price target for Genor Biopharma Holdings Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
1307.13%
EPS Growth Forecast
587.04%